Document:

<PAGE>

                                                                    EXHIBIT 4.11

THE WARRANTS REPRESENTED BY THIS CERTIFICATE AND THE OTHER SECURITIES ISSUABLE
UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED FOR PURPOSES OF PUBLIC
DISTRIBUTION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND MAY
NOT BE OFFERED OR SOLD EXCEPT (i) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT, (ii) TO THE EXTENT APPLICABLE, PURSUANT TO RULE 144
UNDER SUCH ACT (OR ANY SIMILAR RULE UNDER SUCH ACT RELATING TO THE DISPOSITION
OF SECURITIES), OR (iii) UPON THE DELIVERY BY THE HOLDER TO THE COMPANY OF AN
OPINION OF COUNSEL, REASONABLY SATISFACTORY TO COUNSEL FOR THE COMPANY, STATING
THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS AVAILABLE.

THE TRANSFER OR EXCHANGE OF THE WARRANTS REPRESENTED BY THIS CERTIFICATE IS
RESTRICTED IN ACCORDANCE WITH THE WARRANT AGREEMENT REFERRED TO HEREIN.

                           EXERCISABLE ON OR BEFORE
                  5:00 P.M., NEW YORK TIME, November 17, 2004

          No. W-                                               14,829 Warrants

                              WARRANT CERTIFICATE

     This Warrant Certificate certifies that Rene Russnok or registered assigns,
is the registered holder of 14,829 Warrants to purchase, at any time from
November 17, 1999 until 5:00 P.M. New York City time on November 17, 2004
("Expiration Date"), up to 14,829 fully-paid and non-assessable shares
("Shares") of the common shares, par value per share (the "Common Shares"), of
eDiets.com, Inc., a Delaware corporation (the "Company"), at the initial
exercise price, subject to adjustment in certain events (the "Exercise Price"),
of $1.375 per Share upon surrender of this Warrant Certificate and payment of
the Exercise Price at an office or agency of the Company, but subject to the
conditions set forth herein and in the warrant agreement dated as of November
17, 1999 between the Company and Whale Securities Co., L.P., as amended by an
Agreement dated as of March 28, 2001 (the "Warrant Agreement"). Payment of the
Exercise Price may be made in cash, or by certified or official bank check in
New York Clearing House funds payable to the order of the Company, or any
combination thereof.

     No Warrant may be exercised after 5:00 P.M., New York City time, on the
Expiration Date, at which time all Warrants evidenced hereby, unless exercised
prior thereto, shall thereafter be void.

     The Warrants evidenced by this Warrant Certificate are part of a duly
authorized issue of Warrants issued pursuant to the Warrant Agreement, which
Warrant Agreement is hereby incorporated by reference in and made a part of this
instrument and is hereby referred to in a description of the rights, limitation
of rights, obligations, duties and immunities thereunder of the Company and the
holders (the words "holders" or "holder" meaning the registered holders or
registered holder) of the Warrants.
<PAGE>

     The Warrant Agreement provides that upon the occurrence of certain events,
the Exercise Price and the type and/or number of the Company's securities
issuable thereupon may, subject to certain conditions, be adjusted. In such
event, the Company will, at the request of the holder, issue a new Warrant
Certificate evidencing the adjustment in the Exercise Price and the number
and/or type of securities issuable upon the exercise of the Warrants; provided,
however, that the failure of the Company to issue such new Warrant Certificates
shall not in any way change, alter, or otherwise impair, the rights of the
holder as set forth in the Warrant Agreement.

     Upon due presentment for registration of transfer of this Warrant
Certificate at an office or agency of the Company, a new Warrant Certificate or
Warrant Certificates of like tenor and evidencing in the aggregate a like number
of Warrants shall be issued to the transferee(s) in exchange for this Warrant
Certificate, subject to the limitations provided herein and in the Warrant
Agreement, without any charge except for any tax or other governmental charge
imposed in connection therewith.

     Upon the exercise of less than all of the Warrants evidenced by this
Certificate, the Company shall forthwith issue to the holder hereof a new
Warrant Certificate representing such number of unexercised Warrants.

     The Company may deem and treat the registered holder(s) hereof as the
absolute owner(s) of this Warrant Certificate (notwithstanding any notation of
ownership or other writing hereon made by anyone), for the purpose of any
exercise hereof, and of any distribution to the holder(s) hereof, and for all
other purposes, and the Company shall not be affected by any notice to the
contrary.

     All terms used in this Warrant Certificate which are defined in the Warrant
Agreement shall have the meanings assigned to them in the Warrant Agreement.

     IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be
duly executed under its corporate seal.

Dated:  As of March 28, 2001                 EDIETS.COM, INC.

                                             By:_______________________________
                                                    Name:  David R. Humble
                                                    Title:  Chairman and Chief
                                                            Executive Office<PAGE>

                                                                   EXHIBIT 10.66

          Third Agreement and Amendment (the "Agreement"), effective as of
                                              ---------
          January 22, 2001, by and among Incara Pharmaceuticals Corporation, a
          Delaware corporation (the "Company"), Elan International Services,
                                     -------
          Ltd. ("EIS"), a Bermuda exempted limited liability company and a
                 ---
          wholly owned subsidiary of Elan Corporation, plc, an Irish public
          limited liability company ("Elan"), and Elan Pharma International
                                      ----
          Limited, an Irish private limited liability company and a wholly owned
          subsidiary of Elan and an affiliate of EIS ("EPIL").
                                                       ----
          ----------------------------------------------------------------------
                                   RECITALS:

     WHEREAS, the Company, EIS and EPIL have entered into a Securities Purchase
Agreement dated as of December 21, 2000 (as amended from time to time by the
parties thereto, the "Purchase Agreement"), pursuant to which the Company issued
                      ------------------
and sold to EIS, and EIS purchased from the Company, (i) 12,015 shares of the
Company's Series C Preferred Stock, par value U.S.$0.01 per share (the "Series C
                                                                        --------
Preferred Stock"), (ii) a warrant to purchase up to 22,191 shares of the
---------------
Company's Series B Preferred Stock, par value U.S.$0.01 per share (the "Series B
                                                                        --------
Preferred Stock"), (iii) 28,457 shares of Series B Preferred Stock and (iv)
---------------
825,000 shares of common stock, par value U.S.$0.001 per share of the Company
(the "Incara Common Stock"). The Company further issued and sold to EPIL, and
      -------------------
EPIL purchased from the Company, a convertible promissory note of the Company
(the "Note"), amounts in respect of which may be disbursed from time to time in
      ----
an aggregate amount of up to U.S.$4,806,000 in accordance with its terms and
subject to the conditions contained therein and in the Purchase Agreement;

     WHEREAS, the parties desire to amend the Purchase Agreement to limit the
number of shares of Series B Preferred Stock issuable upon attainment of certain
milestones as set forth in the Purchase Agreement; and

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants contained herein, the sufficiency of which is hereby acknowledged, the
parties hereby agree as follows:

     1. The parties agree that the Purchase Agreement shall be amended as
follows:

        1.1  Section 1(f) of the Purchase Agreement is amended by inserting
after the third sentence of Section 1(f) the following two sentences:

        "Notwithstanding the above, in no event during the life of this
     Agreement shall the number of shares of Series B Preferred Stock purchased
     and underlying warrants issued in the Second Closing (it being understood
     that the warrants to be issued in the Second Closing shall be exercisable
     for a number of shares of Series B Preferred Stock equal to 20% of the

                                       1
<PAGE>

     number of shares of Series B Preferred Stock purchased in the Second
     Closing) exceed 150,000 shares (as such number may be adjusted for stock
     splits, combinations, recapitalizations, reclassifications and dividends
     effected subsequent to December 21, 2000, the "Second Closing Maximum
                                                    ----------------------
     Shares"), which represents less than 20% of the Incara Common Stock issued
     ------
     and outstanding on December 21, 2000 (on an as converted basis). If this
     limitation on the amount of Series B Preferred Stock is triggered, the
     Second Purchase Price shall not be $1,000,000 but instead shall be equal to
     the Later Stock Price multiplied by the quotient of (i) the Second Closing
     Maximum Shares divided by (ii) 1.2, and the purchase of Series B Preferred
     Stock and warrants by EIS at the Second Closing shall be in the sole
     discretion of EIS."

          1.2  Section 5(a) of the Purchase Agreement is hereby amended by
     changing the reference to Series B Preferred Stock in the parenthetical in
     the eighth line to a reference to Series C Preferred Stock.

     2.   Existing Representations, Warrants and Covenants. The Company hereby
          ------------------------------------------------
represents and warrants that all representations and warranties contained in the
Purchase Agreement and the Note are true and correct, in all material respects,
and the Company has complied, and is presently in compliance, in all material
respects, with all agreements and covenants set forth in the Transaction
Documents (as defined in the Purchase Agreement), as of the date of this
Agreement.

     3.   Amendment and Waiver. This Agreement may not be modified or amended,
          --------------------
or any of the provisions hereof waived, except by written agreement of the
Company, EIS and EPIL dated after the date hereof.

     4.   Headings. The section and paragraph headings contained in this
          --------
Agreement are for reference purposes only and shall not affect in any way the
meaning or interpretation of the Agreement.

     5.   Entire Agreement. This Agreement and the Transaction Documents contain
          ----------------
the entire understanding of the parties with respect to the subject matter
hereof and thereof and supersede all prior agreements and understandings among
the parties with respect thereto.

     6.   Governing Law. This Agreement shall be governed in all respects by the
          -------------
laws of the State of New York, without giving effect to principles of conflicts
of laws, and in accordance with the terms of Section 13 of the Purchase
Agreement.

     7.   Counterparts. This Agreement may be executed in any number of
          ------------
counterparts, including by facsimile signature, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.

     8.   Expenses. Each of the parties shall be responsible for its own costs
          --------
and expenses incurred in connection with the transactions contemplated hereby.

                                       2
<PAGE>

     9.  Successors and Assigns. The provisions hereof shall inure to the
         ----------------------
benefit of, and be binding upon, the successors and assigns of the parties
hereto.

     10.  Severability. In case any provision of this Agreement shall be
          ------------
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not be in any way affected or impaired thereby.

                     [The next page is the signature page.]

                                       3
<PAGE>

      In Witness Whereof, the parties have caused this Agreement to be executed
as of the date first above written.

                              Incara Pharmaceuticals Corporation

                              By:_______________________________________________

                              Name:_____________________________________________

                              Title:____________________________________________

                              Elan International Services, Ltd.
                              (sole shareholder of Series C Preferred Stock)

                              By:_______________________________________________

                              Name:_____________________________________________

                              Title:____________________________________________

                              Elan Pharma International Limited

                              By:_______________________________________________

                              Name:_____________________________________________

                              Title:____________________________________________

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]